Results 131 to 140 of about 16,645 (269)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism

Global Cardiology Science and Practice, 2014
Venous thromboembolism is associated with a high morbidity and, if left untreated, may progress to fatal outcome. The standard treatment of venous thromboembolism consists of heparin followed by long-term treatment with a vitamin K antagonist. However, the use of vitamin K antagonist has several inherent problems and practical challenges.
openaire   +3 more sources

Edoxaban-induced acute interstitial nephritis. [PDF]

CEN Case Rep
A 76 year-old man with no specific medical history was diagnosed with atrial fibrillation and was started on edoxaban. Seven days after starting edoxaban, renal dysfunction was observed. He was suspected of having anticoagulant-related nephropathy due to acute kidney injury that occurred after starting edoxaban, and a renal biopsy was performed on day ...
Gen S, Higashi R, Nagae N, Kigure R, Kamikubo Y, Nobe K, Ikeda N.   +6 more
europepmc   +3 more sources

Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK [PDF]

, 2016
E. Clay, Aurélien Jamotte, AT Cohen, B van Hout, PD Gumbs, Peter Verhamme   +5 more
openalex   +1 more source

Edoxaban for Cancer-Associated Venous Thromboembolism [PDF]

New England Journal of Medicine, 2018
Gary E, Raskob, Harry R, Büller, Annelise, Segers   +2 more
openaire   +8 more sources

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism [PDF]

, 2016
Zachary A. Stacy, William B. Call, Aaron P. Hartmann, Golden L. Peters, Sara K. Richter   +4 more
openalex   +1 more source

Edoxaban in Latin America

Journal of the American College of Cardiology, 2018
Nicolas Martinenghi, Sergio Dubner
openaire   +3 more sources

Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban [PDF]

, 2016
Takeshi Fuji, Satoru Fujita, Tetsuya Kimura, Kei Ibusuki, Kenji Abe, Shintaro Tachibana, Mashio Nakamura   +6 more
openalex   +1 more source

Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Cardiovascular Therapeutics
Conclusions: This study found that all DOACs provided comparable or superior effectiveness and safety to warfarin. SD apixaban, SD edoxaban, and LD edoxaban achieved a favorable balance between preventing S/SE and MB risk.
Sang-Hyeon Oh, Seunghyun Cheon, Seo-Yong Choi, Young Seo Kim, Han-Gon Choi, Jee-Eun Chung   +5 more
doaj   +1 more source

Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives [PDF]

, 2016
Andrew D. Blann, Giuseppe Boriani, Gregory Y.H. Lip   +2 more
openalex   +1 more source

Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism [PDF]

, 2017
Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as well as for stroke prevention in atrial fibrillation (AF) has been accomplished by vitamin K antagonists for the last half century. Although effective under optimal
Braunwald, Eugene, Steffel, Jan
core